S100A9 and malignant colon neoplasm: In fact, the tumor sphere formation ability was decreased, and the levels of a panel of established CSC markers, including CD133, CD44, Sox2, Oct4, Nanog, and ALDH1A1, were decreased in colon cancer cells treated with GM‐Exo subjected to S100A9 knockdown.